Skip to content


  • Poster presentation
  • Open Access

Neuroprotection by MKK7 inhibition in excitotoxicity

  • Alessandro Vercelli1,
  • Tiziana Borsello2,
  • Alessandra Sclip1,
  • Silvia Biggi1,
  • Ivan Enrico Repetto1,
  • Sara Cimini1,
  • Fabio Falleroni1,
  • Simone Tomasi1,
  • Riccardo Monti1,
  • Noemi Tonna1,
  • Federica Morelli1,
  • Valentina Grande1,
  • Oriano Marin1,
  • Fabio Bianco1 and
  • Daniele di Marino1
SpringerPlus20154(Suppl 1):P53

Published: 12 June 2015



Excitotoxicity following cerebral ischemia elicits a molecular cascade, which leads neurons to death. One key molecule of this pathway is c-Jun-N-terminal kinase (JNK), a MAP kinase, which plays both physiological and pathological roles in neurons. We have previously shown that JNK blockade by specific cell permeable peptide inhibitors significantly reduces infarct size and neuronal death. On the other hand, JNK inhibition may have detrimental side effects due to blockade of its physiological function. Here we have designed a new inhibitor, which blocks MKK7, an upstream activator of JNK, which mediates its pathological activation. This inhibitor was designed taking advantage of the growth arrest and DNA damage inducible 45β (GADD45β) ability to bind MKK7, optimizing the essential domain of GADD45β and linking it with a spacer to TAT peptide sequence to penetrate cells. This inhibitor significantly reduces neuronal death in two in vitro models of excitotoxic cell death, one induced by NMDA exposure and the other by oxygen glucose deprivation. We tested the MKK7 inhibitor in vivo, in two models of permanent ischemia, the one obtained by electrocoagulation, and the other by thromboembolic occlusion of the Middle Cerebral Artery. In both models, it blocked MKK7 activation and provided significant protection, significantly reducing the infarct size when injected 30’ before the lesion. In the electrocoagulation model, we also tested the efficacy of the peptide when injected 6h after lesion, obtaining similar protection. Therefore, we showed that it is possible to prevent JNK activation in excitotoxicity by specific inhibition of MKK7, preserving the physiological role of JNK driven by MKK4. Targeting MKK7 could represent a novel therapeutic strategy for several diseases involving JNK activation.

Authors’ Affiliations

Neuroscience Institute Cavalieri Ottolenghi, Italy
Istituto Mario Negri, Italy


© Vercelli et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.